Transient immunosuppression with deoxyspergualin improves longevity of transgene expression and ability to readminister adenoviral vector to the mouse lung

Human Gene Therapy

Volumn 8, Issue 9, 1997, Pages 1095-1104

  Kaplan, Johanne M ^a   Smith, Alan E ^a  

^a GENZYME CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; BETA GALACTOSIDASE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; METHYLPREDNISOLONE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; IMMUNOSUPPRESSIVE TREATMENT; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TRANSGENE;

ADENOVIRIDAE; ANIMALIA; MIRIDAE;

EID: 0030749713     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.1997.8.9-1095     Document Type: Article

References (58)

1. AMEMIYA, H. (1993). Deoxyspergualin: clinical trials in renal graft rejection. Ann. N.Y. Acad. Sci. 685, 196-201.
2. ARMENTANO, D., SOOKDEO, C.C., HEHIR, K.M., GREGORY, R.J., ST. GEORGE, J.A., PRINCE, G.A., WADSWORTH, S.C., and SMITH, A.E. (1995). Characterization of an adenovirus gene transfer vector containing an E4 deletion. Hum. Gene Ther. 6, 1343-1353.
3. ARMENTANO, D., ZABNER, J., SACKS, C., SOOKDEO, C.C., SMITH, M.P., ST. GEORGE, J.A., WADSWORTH, S.C., SMITH, A.E., and GREGORY, R.J. (1997). Effect of the E4 region on the persistence of transgene expression from adenovirus vectors. J. Virol. 71, 2408-2416.
4. BYRNES, A.P., WOOD, M.J.A., and CHARLTON, H.M. (1996). Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther. 3, 644-651.
5. CRYSTAL, R.G., McELVANEY, N.G., ROSENFELD, M.A., CHU, C.-S., MASTRANGELI, A., HAY, J.G., BRODY, S.L., JAFFE, H.A., EISSA, N.T., and DANEL, C. (1994). Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nature Genet. 8, 42-51.
6. DEMATTEO, R.P., MARKMANN, J.F., KOZARSKY, K.F., BARKER, C.F., and RAPER, S.E. (1996). Prolongation of adenoviral transgene expression in mouse liver by T lymphocyte subset depletion. Gene Ther. 3, 4-12.
7. DONG, J.-Y., WANG, D., VAN GINKEL, F.W., PASCUAL, D.W., and FRIZELL, R.A. (1996). Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector. Hum. Gene Ther. 7, 319-331.
8. FANG, B., WANG, H., GORDON, G., BELLINGER, D.A., READ, M.S., BRINKHOUS, K.M., WOO, S.L.C., and EISENSMITH, R.C. (1996). Lack of persistence of E1-recombinant adenoviral vectors containing a temperature-sensitive E2A mutation in immunocompetent mice and hemophilia B dogs. Gene Ther. 3, 217-222.
9. GOLDMAN, M.J., LITZKY, L.A., ENGELHARDT, J.F., and WILSON, J.M. (1995). Transfer of the CFTR gene to the lung of nonhuman primates with El-deleted, E2a-defective recombinant adenoviruses: a preclinical toxicology study. Hum. Gene Ther. 6, 839-851.
10. GOODING, L.R. (1979). Specificities of killing by T lymphocytes generated against syngeneic SV40 transformants: Studies employing recombinants within the H-2 complex. J. Immunol. 122, 1002-1008.
11. GROTH, C.G., OHLMAN, S.B., ERICZON, G., BARKHOLT, L., and REINHOLT, F.P. (1940). Deoxyspergualin for liver graft rejection. Lancet 336, 626.
12. GUERETTE, B., VILQUIN, J.T., GINGRAS, M., GRAVEL, C., WOOD, K.J., and TREMBLAY, J.P. (1996). Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. Hum. Gene Ther. 7, 1455-1463.
13. HOEGER, P.H., TEPPER, M.A., FAITH, A., HIGGINS, J.A., LAMB, J.R., and GEHA, R.S. (1994). Immunosuppressant deoxyspergualin inhibits antigen processing in monocytes. J. Immunol. 153, 3908-3916.
14. JINDAL, R.M., TEPPER, M.A., SOLTYS, K., and CHO, S.I. (1994). Deoxyspergualin - A novel immunosuppressant. Mount Sinai J. Med. 61, 51-56.
15. JOOS, K., YANG, Y., and WILSON, J.M. (1996) Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum. Gene Ther. 7, 1555-1566.
16. KAPLAN, J.M., ST. GEORGE, J.A., PENNINGTON, S.E., KEYES, L.D., JOHNSON, R.P., WADSWORTH, S.C., and SMITH, A.E. (1996). Humoral and cellular immune responses of nonhuman primates to long-term repeated lung exposure to Ad2/CFTR-2. Gene Ther. 3, 117-127.
17. KAPLAN, J.M., ARMENTANO, D., SPARER, T.E., WYNN, S.G., PETERSON, P.A., WADSWORTH, S.C., COUTURE, K.K., PENNINGTON, S.E., ST. GEORGE, J.A., GOODING, L.R., and SMITH, A.E. (1997). Characterization of factors involved in modulating persistence of transgene expression from recombinant adenovirus in the mouse lung. Hum. Gene Ther. 8, 45-56.
18. KAY, M.A., HOLTERMAN, A.-X., MEUSE, L., GOWN, A., OCHS, H.D., LINSLEY, P.S., and WILSON, C.B. (1995). Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4Ig administration. Nature Genet. 11, 191-197.
19. KOLLS, J.K., LEI, D., ODOM, G., NELSON, S., SUMMER, W.R., GERBER, M.A., and SHELLITO, J.E. (1996). Use of transient CD4 lymhocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors. Hum. Gene Ther. 7, 489-497.
20. LEI, D., LEHMANN, M., SHELLITO, J.E., NELSON, S., SIEGLING, A., VOLK, H.-D., and KOLLS, J.K. (1996). Non-depleting anti-CD4 antibody treatment prolongs lung-directed El-deleted adenovirus-mediated gene expression in rats. Hum. Gene Ther. 7, 2273-2279.
21. LOCHMULLER, H., PETROF, B.J., PARI, G., LAROCHELLE, N., DODELET, V., WANG, Q., ALLEN, C., PRESCOTT, S., MASSIE, B., NALBANTOGLU, J., and KARPATI, G. (1996). Transient immunosuppression by FK506 permits a sustained high-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscles of adult dystrophic (mdx) mice. Gene Ther. 3, 706-716.
22. MOULLIER, P., FRIEDLANDER, G., CALISE, D., RONCO, P., PERRICAUDET, M., and FERRY, N. (1994). Adenoviral-mediated gene transfer to renal tubular cells in vivo. Kidney Int. 45, 1220-1225.
23. NADEAU, K., NADLER, S.G., SAULNIER, M., TEPPER, M., and WALSH, C.T. (1994). Quantitation of the interaction of the immunosuppressant deoxyspergualin and analogs with Hsc70 and Hsp90. Biochemistry 33, 2561-2567.
24. NADLER, S.G., TEPPER, M.A., SCHACTER, B., and MAZZUCO, C.E. (1992). Interaction of the immunosuppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258, 484-486.
25. PHYSICIANS' DESK REFERENCE (1996). Product information (Medical Economics, Montvale, NJ), edition 50, pp. 1275-1279, 2286-2290, 2621-2623.
26. POLLER, W., SCHNEIDER-RASP, S., LIEBERT, U., MERKLEIN, F., THALHEIMER, P., HAACK, A., SCHWAB, R., SCHMITT, C., and BRACKMANN, H.-H. (1996). Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host. Gene Ther. 3, 521-530.
27. QUANTIN, B., PERRICAUDET, L.D., TAJBAKHSH, S., and MANDEL, J.-L. (1992). Adenovirus as an expression vector in muscle cells in vivo. Proc. Natl. Acad. Sci. USA 89, 2581-2584.
28. REES, A.J., and LOCKWOOD, C.M. (1982). Immunosuppressive drugs in clinical practice. In Clinical Aspects of Immunology. P.J. Lachman and D.K. Peters, eds. (Blackwell Scientific, Oxford) pp. 507-564.
29. REICHENSPURNER, H., HILDEBRANDT, A., HUMAN, P.A., BOEHM, D.H., ROSE, A.G., ODELL, J.A., REICHART, B., and SCHORLEMMER, H.U. (1990). 15-Deoxyspergualin for induction of graft nonreactivity after cardiac and renal allotransplantation in primates. Transplantation 50, 181-185.
30. RICH, D.P., COUTURE, L.A., CARDOZA, L.M., GIUGGIO, V.M., ARMENTANO, D., ESPINO, P.C., HEHIR, K., WELSH, M.J., SMITH, A.E., and GREGORY, R.J. (1993). Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4, 461-476.
31. RODNAN, G.P., SCHUMACHER, H.R., and ZVAIFLER, N.J. (1983). Clinical pharmacology of the antirheumatic drugs and Principles in the use of immunosuppressive agents. In Primer on the Rheumatic Diseases. G.P. Rodnan, H.R. Schumacher, and N.J. Zvaifler, eds. (Arthritis Foundation, Atlanta, GA) pp. 188-196.
32. SCARIA, A., ST. GEORGE, J.A., GREGORY, R.J., NOELLE, R.J., WADSWORTH, S.C., SMITH, A.E., and KAPLAN, J.M. (1997). Antibody to CD40 ligand inhibits both humoral and cellular immune responses to adenoviral vectors and facilitates repeated administration to mouse airway. Gene Ther. (in press).
33. SCHORLEMMER, H.U., and SEILER, F.R. (1990). Therapy of human multiple sclerosis. MS disease modifying activity of 15-deoxyspergualin on acute and chronic relapsing experimental allergic encephalomyelitis. Immunobiology 181, 236-237.
34. SCHORLEMMER, H.U., and DICKNEITE, G. (1993). Preclinical studies with 15-deoxyspergualin in various animal models of autoimmune diseases. Ann. N.Y. Acad. Sci. 685, 155-174.
35. SCHORLEMMER, H.U., BARTLETT, R.R., SCHLEYERBACH, R., DICKNEITE, G., SEILER, F.R., and BEHRINGWERKE, A.G. (1989). Immunosuppressive therapy of experimental autoimmune diseases like rheumatoid arthritis and systemic lupus erythematosus by 15-deoxyspergualin. Int. J. Immunother. 5, 9-20.
36. SCHORLEMMER, H.U., DICKNEITE, G., and SEILER, F.R. (1990). Treatment of acute rejection episodes and induction of tolerance in rat skin allotransplantation by 15-deoxyspergualin. Transplant. Proc. 22, 1626-1630.
37. SETOGUCHI, Y., JAFFE, H.A., DANEL, C., and CRYSTAL, R.G. (1994). Ex vivo and in vivo gene transfer to the skin using replication-deficient adenovirus vectors. J. Invest. Dermatol. 102, 415-421.
38. SMITH, T.A.G., WHITE, B.D., GARDNER, J.M., KALEKO, M., and McCLELLAND, A. (1996). Transient immunosuppression permits successful repetitive intravenous administration of an adenovirus vector. Gene Ther. 3, 496-502.
39. SRIVASTAVA, P.K., UDONO, H., BLACHERE, N.E., and LI, Z. (1994). Heat-shock proteins transfer peptides during antigen processing and CTL priming. Immunogenetics 39, 93-98.
40. STROEHMANN, I. (1986). Immunosuppressive therapy of rheumatic diseases. Rheumatology 9, 42-45.
41. SUTO, R., and SRIVASTAVA, P.K. (1995). A mechanism for the specific immunogenicity of heat-shock protein-chaperoned peptides. Science 269, 1585-1588.
42. SUZUKI, S., NISHIMORI, H., KIDO, K., ARITA, S., TASHIRO, H., OHDAN, H., QUINONES, D., and AMEMIYA, H. (1993). Continuous administration of methyldeoxyspergualin prolongs xenograft survival in hamster-to-rat cardiac transplantation. Transplant. Proc. 25, 430-431.
43. TAKAHASHI, K., OTA, K., TANABE, K., OBA, S., TERAOKA, S., TOMA, H., AGISHI, T., KAWAGUCHI, H., and ITO, K. (1990). Effect of a novel immunosuppressive, dexosypergualin, on rejection in kidney transplant recipients. Transplant. Proc. 22, 1606-1612.
44. TEPPER, M.A., NADLER, S.G., ESSELSTYN, J.M., and STERBENZ, K.G. (1995). Deoxyspergualin inhibits κ light chain expression in 70Z/3 pre-B cells by blocking lipopolysaccharide-induced NF-κB activation. I. Immunol. 155, 2427-2436.
45. TRIPATHY, S.K., BLACK, H.B., GOLDWASSER, E., and LEIDEN, J.M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. Nature Med. 2, 545-550.
46. TUFVESON, G., and GANNEDAHL, G. (1994). Deoxyspergualin - A different and intriguing immunosuppressant. Transplant. Proc. 26, 3029-3039.
47. VILQUIN, J.-T., GUERETTE, B., KINOSHlTA, I., ROY, B., GOULET, M., GRAVEL, C., ROY, R., and TREMBLAY, J.P. (1995). FK506 immunosuppression to control the immune reactions triggered by first-generation adenovirus-mediated gene transfer. Hum. Gene Ther. 6, 1391-1401.
48. WALTER, P., BERNHARD, U., SEITZ, G., DICKNEITE, G., and SEDLACEK, H.H. (1987). Xenogeneic heart transplantation with 15-deoxyspergualin: prolongation of graft survival. Transplant. Proc. 19, 3993-3994.
49. WEISS, A. (1993). T lymphocyte activation. In Fundamental Imunology. W.E. Paul, ed. (Raven Press, Ltd., New York, NY) pp. 467-504.
50. YANG, Y., and WILSON, J.M. (1996). CD40 ligand-dependent T cell activation: Requirement of B7-CD28 signaling through CD40. Science 273, 1862-1864.
51. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E., GONCZOL, E., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. Proc. Natl. Acad. Sci. USA 91, 4407-4411.
52. YANG, Y., LI, Q., ERTL, H.C.J., and WILSON, J.M. (1995a). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J. Virol. 69, 2004-2015.
53. YANG, Y., TRINCHIERI, G., and WILSON, J.M. (1995b). Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med. 1, 1-4.
54. YANG, Y., SU, Q., and WILSON, J.M. (1996a). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lung. J. Virol. 70, 7209-7212.
55. YANG, Y., JOOSS, K.U., SU, Q., ERTL, H.C.J., and WILSON, J.M. (1996b). Immune responses to viral antigens versus trangene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. Gene Ther. 3, 137-144.
56. YANG, Y., SU, Q., GREWAL, I.S., SCHILZ, R., FLAVELL, R.A., and WILSON, J.M. (1996c). Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues. J. Virol. 70, 6370-6377.
57. YE, X., ROBINSON, M.B., BATSHAW, M.L., FURTH, E.E., SMITH, I., and WILSON, J.M. (1996). Prolonged metabolic correction in adult omithine transcarbamylae-deficient mice with adenoviral vectors. J. Biol. Chem. 271, 3639-3646.
58. YEI, S., MITTEREDER, N., TANG, K., O'SULLIVAN, C., and TRAPNELL, B.C. (1994). Adenovirus-mediated gene transfer for cystic fibrosis: Quantitative evaluation of repeated in vivo vector administration to the lung. Gene Ther. 1, 192-200.